^
    2d
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    7d
    Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up. (PubMed, Adv Ther)
    These findings inform the long-term comparative efficacy of Bruton tyrosine kinase inhibitors and suggest that zanubrutinib may confer sustained PFS and OS benefits compared with ibrutinib and acalabrutinib in similar treatment-naive CLL populations. Graphical abstract and video available for this article. Overview of the Comparative Efficacy of Covalent BTK Inhibitors in Treatment-Naïve CLL/SLL With Six-Year Follow-Up (MP4 345006 kb).
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib)
    8d
    Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment (clinicaltrials.gov)
    P2, N=138, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    Brukinsa (zanubrutinib) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    9d
    ZeTA: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (clinicaltrials.gov)
    P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)
    10d
    BGB-11417-108: A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. (clinicaltrials.gov)
    P1/2, N=258, Recruiting, BeOne Medicines | N=56 --> 258 | Trial completion date: Dec 2027 --> Nov 2032 | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2027 --> Nov 2029
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    10d
    Composite CLL/SLL and Lymphoplasmacytic Lymphoma with IgM Anti-MAG Neuropathy: Clinicopathologic and Molecular Characterization of a Diagnostically Challenging Case. (PubMed, Ann Clin Lab Sci)
    This case highlights the diagnostic complexity of composite indolent B-cell lymphomas and underscores the importance of integrated clinical, morphologic, immunophenotypic, and molecular assessment to inform management and surveillance.
    Journal • IO biomarker
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    cytarabine • Brukinsa (zanubrutinib)
    10d
    A systematic evaluation of double-expressor lymphoma: prognostic impact, determinants of outcome, and comparative efficacy and safety of novel therapies. (PubMed, Front Oncol)
    Second, a network meta-analysis ranked the efficacy and safety of regimens including rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R); R-CHOP plus lenalidomide (R2-CHOP); R-CHOP plus ibrutinib (I+R-CHOP); R-CHOP plus zanubrutinib (Z+R-CHOP); and R-CHOP plus venetoclax (Ven-R-CHOP). DEL is a distinct high-risk subtype with quantifiable prognostic detriment. Z+R-CHOP emerges as a promising strategy requiring validation in prospective studies.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • etoposide IV • vincristine • prednisone
    16d
    When pseudo-Richter transformation hits the spleen: a case report and literature review. (PubMed, J Hematop)
    Bruton tyrosine kinase inhibidors (BTKI), such as ibrutinib and zanubrutinib, represent a cornerstone of CLL/SLL treatment by inhibiting B-cell receptor signaling. The patient improved after BTKI reintroduction, and a P-RT was diagnosed. Nine similar patients were found through PubMed search, and we describe their clinicopathological characteristics.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib)
    22d
    Pola-ZRCHP: Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes (clinicaltrials.gov)
    P2, N=35, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • Tevimbra (tislelizumab-jsgr) • cyclophosphamide • Brukinsa (zanubrutinib) • prednisone • Polivy (polatuzumab vedotin-piiq)
    1m
    GUIDANCE-10: AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL (clinicaltrials.gov)
    P2, N=178, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • decitabine • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1m
    Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression (clinicaltrials.gov)
    P2, N=41, Recruiting, Huazhong University of Science and Technology | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Brukinsa (zanubrutinib) • vincristine • prednisone
    1m
    MANGROVE: A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=510, Active, not recruiting, BeOne Medicines | Trial completion date: Dec 2027 --> Sep 2031
    Trial completion date
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine